| Date | Time | Source | |
| 03/12/2010 | 1:30PM | DJN | Glaxo Gets EU Approval To Sell Blood Platelet Booster Revolade
U.K.-based GlaxoSmithKline PLC (GSK) said Friday it received approval to market its Revolade drug in Europe to treat a rare clotting disorder that can cause dangerous bleeding. The treatment, also known as eltrombopag, was discovered through a research collaboration between Glaxo and U.S.-based Ligand Pharmaceuticals (LGND... More...>> |
| 03/12/2010 | 12:51PM | DJN | GlaxoSmithKline: EC Gives Marketing Authorization For Revolade
GlaxoSmithKline (GSK.LN) said Friday the European Commission (EC) has granted marketing authorization for Revolade (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP). MAIN FACTS: -Eltrombopag is indicated... More...>> |
| 03/12/2010 | 9:35AM | DJN | GlaxoSmithKline Names Jean Stephenne GSK Biologicals Chairman
GlaxoSmithKline PLC (GSK.LN), the research-based pharmaceutical and healthcare company, said Friday that with immediate effect Jean Stephenne is appointed Chairman, GSK Biologicals. MAIN FACTS: -Stephenne will assume this role in addition to his existing position as President, GSK Biologicals. -Over the next two years... More...>> |
| 03/12/2010 | 3:13AM | DJN | GlaxoSmithKline Sells Entire Shareholding In Maxygen
GlaxoSmithKline PLC (GSK.LN), the U.K. pharmaceutical company, said Friday it sold its entire holding of 1.43 million Common shares, 4.47%, of Maxygen Inc. (MAXY) on March 10 for an undisclosed sum. -Glaxo shares closed Thursday at 1250 pence. -By Ian Walker, Dow Jones Newswires; 44-20-7842-9296; ian.walker@dowjones.com... More...>> |
| 03/11/2010 | 12:40PM | DJN | CORRECT (3/10): FDA Reviews Osteoporosis Drugs For Fracture Risk
The Food and Drug Administration said Wednesday it's conducting a safety review of certain bone-building drugs like Fosamax and Boniva to see if they increase the risk of femur fractures. The review involves a class of drugs known as bisphosphonates, which are commonly prescribed to treat osteoporosis and are designed... More...>> |
| 03/10/2010 | 7:41PM | DJN | 2nd UPDATE: FDA Reviews Osteoporosis Drugs For Fracture Risk
The Food and Drug Administration said Wednesday it's conducting a safety review of certain bone-building drugs like Fosamax and Boniva to see if they increase the risk of femur fractures. The review involves a class of drugs known as bisphosphonates, which are commonly prescribed to treat osteoporosis and are designed... More...>> |
| 03/10/2010 | 5:50PM | DJN | UPDATE: FDA Reviews Osteoporosis Drugs For Fracture Risk
The Food and Drug Administration said Wednesday it's conducting a safety review of certain bone-building drugs like Fosamax and Boniva to see if they increase the risk of femur fractures. The review involves a class of drugs known as bisphosphonates, which are commonly prescribed to treat osteoporosis and are designed... More...>> |
| 03/10/2010 | 4:16PM | DJN | FDA Reviews Osteoporosis Drugs For Fracture Risk
The Food and Drug Administration said Wednesday it's conducting a safety review of certain bone-building drugs like Fosamax and Boniva to see if they increase the risk of femur fractures. The review involves a class of drugs known as bisphosphonates, which are commonly prescribed to treat osteoporosis and are designed... More...>> |
| 03/10/2010 | 5:12AM | DJN | Cellzome In Drug Discovery Alliance With GlaxoSmithKline
Cellzome AG, a privately-owned drug discovery and development company, said Wednesday it has formed a second strategic alliance with GlaxoSmithKline PLC (GSK.LN) giving GSK exclusive access to its proprietary Episphere technology in the emerging field of epigenetics as applied to immunoinflammatory disease. MAIN FACTS:... More...>> |
| 03/09/2010 | 3:20PM | DJN | Amylin, Lilly Diabetes Drug Faces Crucial FDA Decision
After years of anticipation, a long-acting version of diabetes drug Byetta, sold by Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly & Co. (LLY), faces a crucial Food and Drug Administration approval decision this week. Called Byetta LAR, the treatment is injected once a week as opposed to the twice-daily version on... More...>> |
| 03/09/2010 | 12:58PM | DJN | US Health Regulator Wants More Detail On Actelion's Zavesca
Actelion Ltd. (ATLN.VX) said Tuesday the U.S. Food and Drug Administration wants more information on the Swiss firm's Zavesca in treating a rare neurological disease, presenting a potential setback to the drug's approval. The U.S. health regulator wants more preclinical and clinical information on Zavesca, which Actelion... More...>> |
| 03/08/2010 | 9:33PM | DJN | Clinical Setback Forces Restructuring At XenoPort
By Brian Gormley Of Dow Jones VentureWire A clinical setback for XenoPort Inc. (XNPT) could force venture capital firms Maverick Capital and Venrock to wait a while to profit from the $40 million investment they made in the company a little over a year ago. In December 2008, Maverick led and Venrock participated in a $40... More...>> |
| 03/08/2010 | 11:08AM | DJN | UPDATE: GSK: Looking To Grow In India Via Buys, Core Business
GlaxoSmithKline PLC (GSK), the world's second-largest drug maker by prescription drug sales, could expand in India via acquisitions and new drug launches, even as it looks at increasing its manufacturing presence in the country. The U.K.-based firm is undergoing a major transformation under Chief Executive Officer Andrew... More...>> |
| 03/08/2010 | 10:40AM | DJN | US Supreme Court To Weigh Lawsuits For Vaccine Injuries
The U.S. Supreme Court said Monday that it will decide whether a federal law on vaccine injuries shields vaccine makers from certain types of product-liability lawsuits. The high court agreed to consider a Pennsylvania lawsuit in which parents alleged that their 6-month-old daughter developed residual seizure disorder... More...>> |
| 03/08/2010 | 6:46AM | DJN | GlaxoSmithKline: Looking To Grow In India Via Buys, Core Business
GlaxoSmithKline PLC (GSK), the world's second-largest drug maker by prescription drug sales, is looking at expanding in India via both acquisitions and core business growth, its chief executive said Monday. "Opportunities will be evaluated based on a variety of factors, including the strategic nature of the fit," Andrew... More...>> |
| 03/03/2010 | 4:17AM | DJN | Aurobindo Pharma Gets Canada Regulatory OK For Generic Antibiotic
Aurobindo Pharma Ltd. (524804.BY) Wednesday said it has received regulatory approval in Canada to sell a generic antibiotic cefuroxime axetil tablets. Generic cefuroxime axetil tablets are the equivalent of GlaxoSmithKline PLC's Ceftin tablets, which are used for the treatment of mild-to-moderate infections, it said in... More...>> |
| 03/02/2010 | 5:58PM | DJN | UPDATE: Bristol-Myers Operating Chief To Replace Cornelius As CEO
By Peter Loftus Of DOW JONES NEWSWIRES Bristol-Myers Squibb Co. (BMY) Chief Executive James Cornelius will retire in May after a nearly four-year tenure marked by a contrarian strategy of shedding nonpharmaceutical assets while other drug makers diversified and got bigger. The New York company named Lamberto Andreotti... More...>> |
| 03/02/2010 | 12:47PM | DJN | NIH Study Looks At Long-Acting Asthma Drugs For Children
A study found that certain long-acting asthma drugs such as GlaxoSmithKline PLC's (GSK, GSK.LN) Advair were more likely to be the best add-on therapy for children whose asthma isn't well controlled by other drugs. The study, funded by a unit of the National Institutes Health, was designed to help determine which type of... More...>> |
| 03/02/2010 | 4:49AM | DJN | 2nd UPDATE: UCB Net Profit Up More Than Tenfold On One-Time Gain
Belgian pharmaceutical company UCB SA (UCB.BT) said Tuesday that net profit rose more than tenfold in 2009, mainly due to a huge one-time gain from the sale of some older drugs, and said earnings should grow this year as a result of its refocus on three core drugs. UCB said in a statement that total revenue is expected... More...>> |
| 03/02/2010 | 3:49AM | DJN | Glenmark Gets US FDA OK For Ropinirole Hydrochloride Tablets
Glenmark Pharmaceuticals Ltd. (532296.BY) Tuesday said its Glenmark Generics Ltd. unit has received approval from the U.S. Food and Drug Administration to make and sell generic ropinirole hydrochloride tablets. The approval is for ropinirole hydrochloride tablets of 0.25 milligram, 0.5 mg, 1 mg, 2 mg, 3 mg , 4 mg and 5... More...>> |